EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The association between APOE 𝜀4 carrierships and the detection of amyloid positivity using an Alzheimer's disease proteomic blood test in asymptomatic Down syndrome

Lubnaa Badriyyah Abdullah iD, Fan Zhang, Melissa Petersen, James Hall, Benjamin L Handen, Mark Mapstone, Brad Christian, Elizabeth Head, Sigan Harley, Howard Andrews, Joseph H Lee, Dana Tudorascu und 15 weitere

Alzheimer's & Dementia · 2026-04 · 22 (4)

DOI: 10.1002/alz.71338 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 11.04.2026. Verfasst von Lubnaa Badriyyah Abdullah und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, UNT Health Fort Worth, Fort Worth, Texas, USA. Hauptthemen laut MEDLINE: Down Syndrome, Apolipoprotein E4, Amyloid beta-Peptides, Proteomics. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, Investigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (NIH INCLUDE Project), Eunice Kennedy Shriver National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION This study evaluates plasma‐based proteomic profiles for predicting amyloid positivity in adults with Down syndrome (DS) and examines the impact of apolipoprotein E ε4 (APOE ε4) on test performance. METHODS Cross‐sectional data from 290 adults with DS were analyzed using single molecule array (SIMOA) technology to measure plasma amyloid beta (Aβ)42, Aβ40, neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), tau phosphorylated at threonine 181, and total tau. Amyloid burden was quantified using Pittsburgh Compound B and (18)F‐florbetapir Aβ positron emission tomography. Support vector machine analyses were conducted with biomarkers as predictors and age, sex, and APOE ε4 carrier status as covariates. RESULTS Age, GFAP, and NfL contributed the most to the model performance. The proteomic profile achieved an area under the curve (AUC) of 96% in models with and without APOE ε4. DISCUSSION These findings suggest that plasma proteomic biomarkers can effectively identify amyloid positivity in adults with DS and may support clinical triage, monitoring, and selection for clinical trials, independent of APOE ε4 status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Down SyndromeApolipoprotein E4Amyloid beta-PeptidesProteomicsAlzheimer DiseaseHumansFemaleMalePositron-Emission TomographyCross-Sectional StudiesBiomarkersAdultMiddle Agedtau ProteinsNeurofilament ProteinsPeptide FragmentsAniline CompoundsEthylene GlycolsHeterozygoteCarbolinesSupport Vector Machine

Stichwörter der Autor:innen

Alzheimer's diseaseDown syndromeamyloid positron emission tomographyblood‐based biomarker testproteomicssupport vector machine learning

Substanzen

Apolipoprotein E4Amyloid beta-PeptidesBiomarkerstau ProteinsNeurofilament ProteinsPeptide Fragmentsamyloid beta-protein (1-42)neurofilament protein LAniline CompoundsEthylene Glycols

Autor:innen und Institutionen

  • Department of Family Medicine, UNT Health Fort Worth, Fort Worth, Texas, USA.
  • Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Neurology, University of California, Irvine, California, USA.
  • Department of Pediatrics, University of California, Irvine, School of Medicine, Orange, California, USA.
  • University of Wisconsin Madison, Waisman Center, Madison, Wisconsin, USA.
  • Department of Neurology New York, Columbia University, Vagelos College of Physicians and Surgeons, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, New York, New York, USA.

ORCID-Profile: Lubnaa Badriyyah Abdullah

Förderung

  • NIA NIH HHS
  • Investigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (NIH INCLUDE Project)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development

Zitieren

APA

Abdullah, L. B., Zhang, F., Petersen, M., Hall, J., Handen, B. L., Mapstone, M., Christian, B., Head, E., Harley, S., Andrews, H., Lee, J. H., Tudorascu, D., Hom, C., Zaman, S., Brickman, A. M., Rosas, D., Cohen, A., Harp, J. P., Schmitt, F., …, & Ances, B. M. (2026). The association between APOE 𝜀4 carrierships and the detection of amyloid positivity using an Alzheimer's disease proteomic blood test in asymptomatic Down syndrome. Alzheimer's & Dementia, 22(4). https://doi.org/10.1002/alz.71338

Vancouver

Abdullah LB, Zhang F, Petersen M, Hall J, Handen BL, Mapstone M, et al. The association between APOE 𝜀4 carrierships and the detection of amyloid positivity using an Alzheimer's disease proteomic blood test in asymptomatic Down syndrome. Alzheimer's & Dementia. 2026;22(4). doi:10.1002/alz.71338

BibTeX
@article{Abdullah2026,
  author = {Abdullah, Lubnaa Badriyyah and Zhang, Fan and Petersen, Melissa and Hall, James and Handen, Benjamin L and Mapstone, Mark and Christian, Brad and Head, Elizabeth and Harley, Sigan and Andrews, Howard and Lee, Joseph H and Tudorascu, Dana and Hom, Christy and Zaman, Shahid and Brickman, Adam M and Rosas, Diana and Cohen, Annie and Harp, Jordan P and Schmitt, Frederick and Ptomey, Lauren and Burns, Jeffrey M and Lott, Ira T and Lai, Florence and Laymon, Charles and Cruchaga, Carlos and O'Bryant, Sid and Ances, Beau M},
  title = {The association between APOE 𝜀4 carrierships and the detection of amyloid positivity using an Alzheimer's disease proteomic blood test in asymptomatic Down syndrome},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  volume = {22},
  number = {4},
  doi = {10.1002/alz.71338}
}
Kostenlos starten →